Statera BioPharma Inc (STAB)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Michael K. Handley
Employees:
20
2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS, CO, 80526
(888) 613-8802

Statera BioPharma, Inc. develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (Stat-401), and COVID-19 (stat-205) as well as expanding into fibromyalgia and multiple sclerosis.

Data derived from most recent annual or quarterly report
Market Cap 4.974 Million Shares Outstanding54.662 Million Avg 30-day Volume 1.875 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.07
Price to Revenue1.924 Debt to Equity-0.6291 EBITDA-92.33 Million
Price to Book Value0.0 Operating Margin-2391.6502 Enterprise Value13.059 Million
Current Ratio0.055 EPS Growth0 Quick Ratio0.031
1 Yr BETA 1.2031 52-week High/Low 2.15 / 0.08 Profit Margin-2490.946
Operating Cash Flow Growth31.1164 Free Cash Flow to Firm (FCFF) TTM 23.085 Million Free Cash Flow to Equity (FCFE) TTM-51.237 Million
Altman Z-Score-41.3672
View SEC Filings from STAB instead.

View recent insider trading info

Statera BioPharma Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding STAB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding STAB

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2022-03-21 by CHANDRASEKHAR SATISHCHANDRAN
  • 4: filed on 2021-10-19 by BARBARICK STEVE K
  • 4: filed on 2021-10-19 by VERNY LEA
  • 4: filed on 2021-09-30 by MARKVICKA TAUNIA
  • 4: filed on 2021-08-04 by HANDLEY MICHAEL K
  • 3: filed on 2021-08-04 by HANDLEY MICHAEL K
  • 4: filed on 2021-07-29 by Buckheit Robert
  • 4: filed on 2021-07-29 by Selsky Clifford
  • 4: filed on 2021-07-29 by McAvoy Cozette M.
  • 4: filed on 2021-07-29 by ARONSTAM PETER

    • Events (8k)

  • 8-K: filed on 2023-02-01:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-20:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-27:
    Item 8.01: Other Events
  • 8-K: filed on 2022-10-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-27:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K/A: filed on 2022-09-23:
    Item 4.01: Changes in Registrant's Certifying Accountant
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.02: Unregistered Sales of Equity Securities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CHANDRASEKHAR SATISHCHANDRAN

    • Director
    		 0 2022-02-22 0

    MARKVICKA TAUNIA CHIEF OPERATING OFFICER

    • Officer
    • Director
    		 100,000 2021-09-28 0

    BARBARICK STEVE K

    • Director
    		 60,000 2021-09-09 0

    SALUCK RANDY S.

    • Director
    		 60,140 2021-09-09 0

    VERNY LEA

    • Director
    		 60,000 2021-09-09 0

    ARONSTAM PETER CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2021-07-27 0

    HANDLEY MICHAEL K PRESIDENT AND CEO

    • Officer
    • Director
    		 296,609 2021-07-27 0

    SELSKY CLIFFORD CHIEF MEDICAL OFFICER

    • Officer
    		 0 2021-07-27 0

    MCAVOY COZETTE M. CHIEF LEGAL OFFICER

    • Officer
    		 0 2021-07-27 0

    BUCKHEIT ROBERT CHIEF TECHNOLOGY OFFICER

    • Officer
    		 0 2021-07-27 0

    MILLER LANGDON L CHIEF MEDICAL OFFICER

    • Officer
    		 0 2021-07-22 0

    ZOSH CHRISTOPHER VICE PRESIDENT OF FINANCE

    • Officer
    		 0 2019-12-13 0

    FEDYUNIN IVAN

    • Director
    		 0 2018-08-10 0

    SZYDLO JOHN EDWARD PRINCIPAL FINANCIAL OFFICER

    • Officer
    		 273 2017-04-21 0

    ANDRYUSHECHKIN ALEXANDER

    • Director
    		 0 2016-07-21 0

    TALYANSKIY DANIIL

    • Director
    		 0 2016-07-21 0

    NECHAEV ALEXEY

    • Director
    		 0 2016-04-14 0

    PERSIYANOV IVAN

    • Director
    		 0 2015-07-09 0

    EVDOKIMOVA ANNA

    • Director
    		 0 2015-07-09 0

    LEBEDINA YULIA

    • Director
    		 0 2015-07-09 0

    GORSHKOV KONSTANTIN

    • Director
    		 0 2015-07-09 0

    SARAEVA NATALIA

    • Director
    		 0 2015-07-09 0

    KHUDYK NATALIA

    • Director
    		 0 2015-07-09 0

    LEVINA TATIANA

    • Director
    		 0 2015-07-09 0

    ANTAL JAMES

    • Director
    		 0 2015-04-22 0

    LYONS C NEIL CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2015-04-22 0

    PRINCIPI ANTHONY

    • Director
    		 0 2015-04-22 0

    GUDKOV ANDREI V CHIEF SCIENTIFIC OFFICER

    • Officer
    • Director
    		 0 2015-04-22 0

    KOGAN YAKOV CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2015-04-22 0

    MCGOWAN RICHARD

    • Director
    		 0 2015-04-22 0

    KASIMOVA ELENA

    • Director
    		 0 2015-04-22 0

    BROWN JULIA R

    • Director
    		 116,482 2015-01-08 0

    MOGUTOV MIKHAIL

    • 10% Owner
    		 5,286,344 2014-06-20 0

    HOTH DANIEL FLOYD JR

    • Director
    		 0 2014-06-11 0

    POLINSKY ALEXANDER

    • Director
    		 0 2014-06-11 0

    HOHN DAVID C

    • Director
    		 43,049 2014-03-13 0

    DICORLETO PAUL E

    • Director
    		 41,968 2013-06-19 0

    FONSTEIN MICHAEL PRESIDENT

    • Officer
    • Director
    		 0 2013-05-13 0

    VIALLET JEAN CHIEF DEVELOPMENT OFFICER

    • Officer
    		 0 2013-04-03 0

    KASTEN BERNARD L

    • Director
    		 0 2012-10-25 0

    MARHOFER JOHN A JR CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2011-03-21 0

    PEREZ HECTOR DANIEL

    • Director
    		 12,749 2010-06-08 0

    SUNRISE SECURITIES CORP

    • 10% Owner
    		 5,000 2007-10-15 0

    ANTAL JAMES J

    • Director
    		 0 2006-07-25 0

    SUNRISE EQUITY PARTNERS LP

    • 10% Owner
    		 55,634 2006-07-20 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    STATERA BIOPHARMA INC STAB 2023-11-28 22:15:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 21:45:03 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 21:15:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 20:45:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 20:15:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 19:45:03 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 19:15:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 18:45:03 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 18:15:03 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 17:45:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 17:15:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 16:45:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 16:15:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 15:45:03 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 15:15:03 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 14:45:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 14:15:04 UTC -20.6567 25.9767 550000
    STATERA BIOPHARMA INC STAB 2023-11-28 13:45:04 UTC -20.7152 26.0352 450000
    STATERA BIOPHARMA INC STAB 2023-11-28 13:15:03 UTC -20.7152 26.0352 450000
    STATERA BIOPHARMA INC STAB 2023-11-28 12:45:04 UTC -20.7152 26.0352 450000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments